FDA advisory panel backs most peptide therapies, but regulatory path remains uncertain
An FDA advisory committee voted to support the compounding of six out of seven experimental peptide drugs, prompting industry speculation about faster approval routes while scientists warn of limited safety data.
An FDA advisory panel voted in favor of allowing compounding of six of seven peptide therapies, including BPC-157, TB-500 and MOTS-c, after a marathon hearing in late July. The recommendation does not immediately legalize production; the agency’s staff must still review the data before deciding whether compounding pharmacies may manufacture the compounds.
Dr. Jessica Duncan, chief medical officer of telehealth provider IVIM Health, said patients are now “even more curious” and that the timeline for availability remains uncertain. Legal analyst Jesse Dresser noted that the FDA typically follows advisory committee advice but may seek faster pathways than the standard rulemaking process, which can take months to over a year.
One possible interim step is placing the peptides on the FDA’s “Category One” list, which would permit compounding while formal rulemaking proceeds. Former FDA official Ilisa Bernstein cautioned that the agency must base any decision on the scientific data, emphasizing the need for safety oversight.
Industry lawyers warned that the agency could face lawsuits either for approving the peptides or for maintaining the current prohibition. Abha Kundi observed that the market is already saturated with unregulated products marketed for “research purposes,” a practice she described as “seedier than people think.”
The peptides are promoted in the wellness and longevity sectors for uses such as injury recovery and performance enhancement, but none have completed large-scale human trials required for full drug approval. If the FDA permits compounding, the drugs would be prescription-only and supplied by specialty compounding pharmacies rather than retail chains, a transition that could take several months according to Scott Brunner of the Alliance for Pharmacy Compounding.
Physicians expressed mixed views. Dr. Harmeet Narula said commercial enthusiasm appears to outpace clinical evidence, while Dr. Haleem Mohammed, who voted with the panel, argued the meeting did not fully present existing data and called the move “about moving towards a regulated pathway for peptides that patients are already using.”